Daré Bioscience Faces Nasdaq Listing Compliance Challenges
I'm LongbridgeAI, I can summarize articles.Daré Bioscience (DARE) received a Nasdaq notice of non-compliance with Listing Rule 5550(b) due to stockholders' equity falling below $2.5 million, risking delisting. The company has requested a hearing to seek an extension. This uncertainty may impact liquidity and capital access. Analysts maintain a 'Buy' rating with an $8.00 target, while TipRanks' AI assigns a 'Neutral' score citing weak financials and technical indicators despite positive clinical progress.
Daré Bioscience ( (DARE) ) has provided an announcement.
On July 13, 2026, Daré Bioscience was notified by Nasdaq that it no longer complies with Listing Rule 5550(b) after reporting stockholders’ equity below $2.5 million in its Form 10-Q for the quarter ended March 31, 2026 and failing to meet alternative market value or net income thresholds. As a result, its common stock is subject to potential delisting, and the company’s plan to request a hearing before a Nasdaq panel introduces uncertainty for investors over whether it can secure an extension and ultimately maintain its Nasdaq listing.
The outcome of the hearing process may affect Daré Bioscience’s access to public capital markets and visibility among institutional investors, with any delisting likely to constrain liquidity and raise its cost of capital. Stakeholders face heightened risk as the company navigates compliance challenges that could weaken its market positioning in the competitive biopharmaceutical sector if it cannot regain adherence to Nasdaq’s listing standards.
The most recent analyst rating on (DARE) stock is a Buy
with a $8.00 price target.
To see the full list of analyst forecasts on Daré Bioscience stock,
see the DARE Stock Forecast page.
Spark’s Take on DARE Stock
According to Spark, TipRanks’ AI Analyst, DARE is a Neutral.
The score is held down primarily by very weak financial performance (large losses, negative cash flow, and thin/volatile equity implying ongoing funding/dilution risk). Technicals are also soft with price below key moving averages and negative MACD. These are partially offset by a more positive earnings call narrative driven by near-term commercialization milestones and ongoing clinical progress, though liquidity and execution risks remain prominent.
To see Spark’s full report on DARE stock,
click here.
More about Daré Bioscience
Daré Bioscience, Inc. is a biopharmaceutical company focused on developing and commercializing products in the women’s health sector. Its portfolio targets conditions in areas such as contraception, fertility, and reproductive health, aiming to address unmet medical needs and secure a position in specialized healthcare markets.
Average Trading Volume: 438,093
Technical Sentiment Signal: Strong Sell
Current Market Cap: $29.06M